APPLICATION
ANDA086183
TYPE
ANDA
ORIGINAL APPROVAL
1981-12-14
LATEST ACTION
2021-02-16
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
HYDROXYZINE PAMOATEPrescription
HYDROXYZINE PAMOATE EQ 50MG HYDROCHLORIDE · CAPSULE · ORAL
Approval history
2021-02-16Labeling · Supplement 40 · standardAP
2021-02-16Labeling · Supplement 39 · standardAP
2015-01-24Labeling · Supplement 37 · standardAP
2013-07-22Labeling · Supplement 32 · standardAP
2002-12-20Labeling · Supplement 24AP
2000-02-02Manufacturing (CMC) · Supplement 23AP
1996-06-24Labeling · Supplement 22AP
1996-05-22Labeling · Supplement 20AP
1996-04-12Manufacturing (CMC) · Supplement 21AP
1995-03-03Manufacturing (CMC) · Supplement 17AP
1995-03-03Manufacturing (CMC) · Supplement 18AP
1994-12-12Manufacturing (CMC) · Supplement 15AP
1994-12-12Manufacturing (CMC) · Supplement 12AP
1994-12-09Manufacturing (CMC) · Supplement 14AP
1994-12-09Manufacturing (CMC) · Supplement 19AP
1992-07-28Labeling · Supplement 16AP
1989-05-09Labeling · Supplement 11AP
1986-01-17Manufacturing (CMC) · Supplement 8AP
1986-01-17Manufacturing (CMC) · Supplement 9AP
1982-12-09Manufacturing (CMC) · Supplement 6AP
1982-12-09Manufacturing (CMC) · Supplement 5AP
1982-12-09Manufacturing (CMC) · Supplement 1AP
1981-12-14OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.